Evommune, Inc. (EVMN)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 48
- Market Cap
- $409M
About Evommune, Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
SentiSense also tracks daily options readings for Evommune, Inc.: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Evommune, Inc. stock analysis, sentiment tracking, and market intelligence on SentiSense.